Replies to post #89037 on Biotech Values

[floblu14]

January 13, 2010

08:58 EDT MNTA theflyonthewall.com: Momenta Pharma valuation attractive, says Oppenheimer
After meeting with Momenta's management, Oppenheimer believes that the company's M-enoxaparin may be the sole generic treatment approved. The firm thinks the stock is undervalued even if M-enoxaparin is one of multiple generics approved, and it predicts that the stock will increase dramatically if it is the sole generic. The firm maintains an Outperform rating

http://www.theflyonthewall.com/permalinks/entry.php/MNTAid1184358